Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Review Vytorin Data: ENHANCEd Label To Follow?

Executive Summary

FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25
Advertisement

Related Content

FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”
FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
Vytorin and Zetia add depression to labels
Vytorin and Zetia add depression to labels
GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
Merck Unsure Whether Vytorin, Zetia Can Cushion Fosamax’s Patent Loss
Assault On Drug Marketing Tactics Becomes Drug-Specific On Capitol Hill
Assault On Drug Marketing Tactics Becomes Drug-Specific On Capitol Hill
Advertisement
UsernamePublicRestriction

Register

PS049231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel